跳至主要内容
临床试验/NCT05026632
NCT05026632进行中(未招募)1 期

Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy

Nacuity Pharmaceuticals, Inc.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年1月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30
试验地点
1
主要终点
Lens Densitometry

研究概览

简要总结

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Indicated for vitrectomy
  • Natural Lens in place at time of vitrectomy
  • Some cataract present as assessed pre-operatively

排除标准

  • Previous intraocular surgery in study eye.
  • Clear zonular weakness or defects / coloboma.
  • Not on stable dose of medications for other conditions.
  • Need for oral corticosteroids during study participation.
  • Evidence or history of uveitis, or ocular ischemia.
  • Current smoker
  • Use of supplemental oxygen
  • Evidence or history of proliferative diabetic retinopathy.
  • Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation.
  • Sensitivity to thiol compounds.
  • Participation in another clinical trial.

研究组 & 干预措施

Control

No Intervention

No implant inserted at time of vitrectomy

Double NPI-002 Intravitreal Implant

Experimental

two NPI-002 implants inserted at the time of vitrectomy

干预措施: NPI-002 Intravitreal Implant (Drug)

Single NPI-002 Intravitreal Implant

Experimental

one NPI-002 implant inserted at the time of vitrectomy

干预措施: NPI-002 Intravitreal Implant (Drug)

结局指标

主要结局

Lens Densitometry

时间窗: 6 months

Change from Baseline

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验